They further suggest that by blocking ACPSV production (i.e., by targeting Crk), or by interfering with ACPSV action (i.e., through the use of JNK inhibitors), we may be able to enhance the effectiveness of current cancer therapeutics. The gene discussed is CRK; the disease is cancer.